Protheragen, a global innovation incubator and go-global platform for biotech, has entered into a strategic partnership with Zencore Biologics, a leading biologics CDMO in China. The two parties will establish a synergistic model combining “go-global support with manufacturing capabilities,” leveraging Protheragen’s expertise in advancing Chinese innovation projects into global market and its extensive international client networks, with Zencore’s full-spectrum biologics CDMO services. Through this collaboration, the partners aim to build an efficient, compliant, and globally integrated ecosystem for biologics R&D and manufacturing.
Headquartered in New York, Protheragen is a global pharmaceutical and biomedical group dedicated to accelerating the overseas translation and international expansion of innovative drug projects from China. Led by biomedical Ph.D. graduates from top U.S. universities, the company bring over a decade of cross-border experience, having served more than 200 client companies and successfully managing over 130 high-end projects spanning antibodies, small molecules, ADCs, and cell and gene therapies, representing more than 600 assets. Protheragen not only provides incubation and channel support for Chinese projects targeting international markets but also leverages a strong network of overseas innovative drug client built through years of industry engagement.
Zencore Biologics is a premier biologics CDMO in China, offering end-to-end services spanning stable cell line development, process development, GMP pilot production and commercial manufacturing. The company operates large-scale GMP-compliant manufacturing facilities and has achieved an industry-leading antibody expression titer of over 15 g/L in fed-batch production.
Under the agreement, the two parties will implement a “client referral + manufacturing service” collaboration model: Protheragen will precisely match its overseas innovative drug clients and projects to Zencore, which will provide high-quality CDMO manufacturing services. In parallel, Protheragen will continue to leverage its go-global platform capabilities to support promising Chinese biotech projects in entering international markets. Through this model, both parties achieve efficient alignment of client resources and manufacturing capabilities, creating a true “1+1>2” synergy. This model enables efficient alignment between global client demand and advanced manufacturing capacities.
This partnership deeply integrates Protheragen’s cross-border go-global expertise and client channel advantages with Zencore’s biologics CDMO platform and large-scale manufacturing capabilities. Overseas projects introduced by Protheragen will benefit from Zencore’s high-quality, efficient manufacturing support to accelerate into clinical and commercial stages. In return, Zencore will further expand its international client base and elevate its international service level and accelerate its integration into global innovative drug supply chain through Protheragen’s go-global network and project referrals.
Together, the two companies are committed to building an open, win-win global ecosystem for biologics innovation and manufacturing — helping Chinese innovative drug projects reach global markets while providing overseas clients with a leading CDMO solution from China.
Protheragen Inc., headquartered in New York, is a global pharmaceutical and biomedical group dedicated to providing comprehensive international expansion support and innovative drug project incubation services for biotech and pharmaceutical companies. Led by biomedical Ph.D. graduates from top U.S. universities, the company focuses on enabling Chinese innovative drug projects to go global, while also sourcing high-potential biomedical innovations worldwide across areas including drug R&D, medical devices, and smart healthcare. To date, Protheragen has served over 200 clients, successfully managed 130+ high-end projects, and covered more than 600 assets.
Founded in 2017 and registered in the Shanghai Lingang Free Trade Zone, Zencore Biologics is an independent CDMO dedicated to offering one-stop services from clinical development to commercial manufacturing for global biopharmaceutical clients. Its core capabilities span large-molecule biologics CDMO, ADC CDMO, media development and production, analytical testing, and quality & regulatory affairs. To date, Zencore has served over 100 clients and completed more than300projects. Embracing the corporate philosophy of “Grasp the Essence, Achieve the Best,” Zencore is committed to enabling patients worldwide to access high-quality biologics through exceptional processes.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
